Janus Henderson Cuts AN2 Therapeutics Stake to Zero Voting Shares
Ticker: ANTX · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1880438
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, stake-reduction, SC-13G/A, biotech
TL;DR
**Janus Henderson dumped their AN2 Therapeutics voting shares, watch out!**
AI Summary
Janus Henderson Group plc, a global investment manager, filed an amended SC 13G/A on February 12, 2024, indicating a change in their beneficial ownership of AN2 Therapeutics, Inc. (0001880438) common stock as of December 31, 2023. While the filing doesn't specify the exact change, it states they now hold 0 shares with sole voting power, suggesting a significant reduction or complete divestment of their previous holdings. This matters to investors because a major institutional investor like Janus Henderson reducing its stake could signal a loss of confidence in AN2 Therapeutics' future prospects, potentially leading to downward pressure on the stock price.
Why It Matters
A large institutional investor like Janus Henderson reducing its stake to zero voting shares could signal a lack of confidence in AN2 Therapeutics, potentially impacting investor sentiment and stock performance.
Risk Assessment
Risk Level: medium — The divestment by a major institutional investor like Janus Henderson could indicate underlying concerns about AN2 Therapeutics, posing a moderate risk to current and prospective shareholders.
Analyst Insight
A smart investor would investigate the reasons behind Janus Henderson's significant reduction in their AN2 Therapeutics stake and consider if this signals a fundamental issue before making any investment decisions.
Key Numbers
- 0 — Sole Voting Power Shares (Janus Henderson Group plc now holds zero shares with sole voting power in AN2 Therapeutics, Inc.)
- 12/31/2023 — Date of Event (This is the effective date of the ownership change reported by Janus Henderson Group plc.)
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person filing the SC 13G/A, a global investment manager
- AN2 Therapeutics, Inc. (company) — the subject company whose common stock is being reported on
- 037326105 (number) — the CUSIP number for AN2 Therapeutics, Inc. Common Stock
- December 31, 2023 (date) — the date of the event requiring the filing of this statement
- 0 (number) — the number of shares with sole voting power held by Janus Henderson Group plc
Forward-Looking Statements
- AN2 Therapeutics' stock price may experience downward pressure in the short term. (AN2 Therapeutics, Inc.) — medium confidence, target: 3 months
- Other institutional investors might re-evaluate their positions in AN2 Therapeutics. (Institutional Investors) — medium confidence, target: 6 months
FAQ
What is the primary purpose of this SC 13G/A filing by Janus Henderson Group plc?
The primary purpose of this SC 13G/A filing is to amend a previous Schedule 13G, indicating a change in beneficial ownership of AN2 Therapeutics, Inc. common stock by Janus Henderson Group plc as of December 31, 2023, specifically noting they now hold 0 shares with sole voting power.
Which company is the subject of this ownership report?
The subject company of this ownership report is AN2 Therapeutics, Inc., identified by CIK 0001880438 and CUSIP 037326105.
What is the reported number of shares with sole voting power held by Janus Henderson Group plc in AN2 Therapeutics, Inc.?
As per the filing, Janus Henderson Group plc holds 0 shares with sole voting power in AN2 Therapeutics, Inc. as of December 12/31/2023.
Under which rules is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b) and Rule 13d-1(c) of the Securities Exchange Act of 1934, as indicated by the checked boxes in the filing.
When was the event that required this filing?
The date of the event which requires the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding AN2 Therapeutics, Inc. (ANTX).